0.35
+0.0177(+5.33%)
Currency In USD
| Previous Close | 0.33 |
| Open | 0.34 |
| Day High | 0.35 |
| Day Low | 0.33 |
| 52-Week High | 1.65 |
| 52-Week Low | 0.29 |
| Volume | 687,058 |
| Average Volume | 4.53M |
| Market Cap | 27.45M |
| PE | -0.92 |
| EPS | -0.38 |
| Moving Average 50 Days | 0.5 |
| Moving Average 200 Days | 0.81 |
| Change | 0.02 |
If you invested $1000 in Clearside Biomedical, Inc. (CLSD) since IPO date, it would be worth $48.22 as of September 12, 2025 at a share price of $0.35. Whereas If you bought $1000 worth of Clearside Biomedical, Inc. (CLSD) shares 5 years ago, it would be worth $210.6 as of September 12, 2025 at a share price of $0.35.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Clearside Biomedical Announces Multiple Presentations on Suprachoroidal Delivery to be Featured at the 25th EURETINA Congress
GlobeNewswire Inc.
Aug 26, 2025 12:05 PM GMT
- Presentations Highlight the Versatility of Clearside’s SCS Microinjector® Platform for the Treatment of Multiple Retinal Diseases - - CLS-AX Trial Designs in Wet AMD and Diabetic Retinopathy to be Featured in Presentation by Dr. Sobha Sivaprasad -
Clearside Biomedical Announces Approval of XIPERE® Suprachoroidal Treatment for Uveitic Macular Edema in Canada
GlobeNewswire Inc.
Jul 23, 2025 11:05 AM GMT
- XIPERE Now Approved for Use in Multiple Global Markets - - Continued Global Expansion and Validation of Clearside’s Suprachoroidal Space Injection Platform Featuring its Commercially Proven SCS Microinjector® - ALPHARETTA, Ga., July 23, 2025 (GLO
Clearside Biomedical Announces Plan to Explore Strategic Alternatives to Advance its Proprietary Suprachoroidal Space (SCS®) Delivery Platform and Promising Ophthalmology Pipeline
GlobeNewswire Inc.
Jul 17, 2025 11:05 AM GMT
- Proven In-Office, Repeatable, Non-Surgical Procedure for the Targeted Delivery of a Wide Variety of Therapies for Serious Retinal Diseases - - CLS-AX Phase 3-Ready Asset with Global Investigator Support and FDA Alignment on Pivotal Trial Program in